Copyright © 2008 Flemming Brandt Sorensen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. S. M. Bentzen, H. S. Poulsen, S. Kaae, et al., “Prognostic factors in osteosarcomas. A regression analysis,” Cancer, vol. 62, no. 1, pp. 194–202, 1988. View at Publisher · View at Google Scholar
2. W. F. Taylor, J. C. Ivins, K. K. Unni, J. W. Beabout, H. J. Golenzer, and L. E. Black, “Prognostic variables in osteosarcoma: a multi-institutional study,” Journal of the National Cancer Institute, vol. 81, no. 1, pp. 21–30, 1989. View at Publisher · View at Google Scholar
3. D. B. Glasser, J. M. Lane, A. G. Huvos, R. C. Marcove, and G. Rosen, “Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience,” Cancer, vol. 69, no. 3, pp. 698–708, 1992. View at Publisher · View at Google Scholar
4. P. Bieling, N. Rehan, P. Winkler, et al., “Tumor size and prognosis in aggressively treated osteosarcoma,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 848–858, 1996.
5. S. Ferrari, F. Bertoni, M. Mercuri, et al., “Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute,” Annals of Oncology, vol. 12, no. 8, pp. 1145–1150, 2001. View at Publisher · View at Google Scholar
6. A. M. Davis, R. S. Bell, and P. J. Goodwin, “Prognostic factors in osteosarcoma: a critical review,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 423–431, 1994.
7. S. S. Bielack, B. Kempf-Bielack, G. Delling, et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar
8. M. Salzer-Kunstschik, G. Brand, and G. Delling, “Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren,” Pathologe, vol. 4, no. 3, pp. 135–141, 1983.
9. P. Picci, G. Bacci, M. Campanacci, et al., “Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor,” Cancer, vol. 56, no. 7, pp. 1515–1521, 1985. View at Publisher · View at Google Scholar
10. R. Jong, A. M. Davis, M. G. Mendes, J. S. Wunder, R. S. Bell, and R. Kandel, “Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases,” Sarcoma, vol. 4, no. 1-2, pp. 47–55, 2000. View at Publisher · View at Google Scholar · View at PubMed
11. N. Gokgoz, J. S. Wunder, S. Mousses, S. Eskandarian, R. S. Bell, and I. L. Andrulis, “Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma,” Cancer, vol. 92, no. 8, pp. 2181–2189, 2001. View at Publisher · View at Google Scholar
12. N. Baldini, K. Scotlandi, G. Barbanti-Bròdano, et al., “Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome,” The New England Journal of Medicine, vol. 333, no. 21, pp. 1380–1385, 1995. View at Publisher · View at Google Scholar
13. I. J. Lewis, M. A. Nooij, J. Whelan, et al., “Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup,” Journal of the National Cancer Institute, vol. 99, no. 2, pp. 112–128, 2007. View at Publisher · View at Google Scholar · View at PubMed
14. E. Mantadakis, G. Kim, J. Reisch, et al., “Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma,” Journal of Pediatric Hematology Oncology, vol. 23, no. 5, pp. 286–289, 2001. View at Publisher · View at Google Scholar
15. D. Wang, L. Chen, and F. Gao, “Correlation of tumor microvesseldensity with prognosis in osteogenic sarcoma,” Zhonghua Bing Li Xue Za Zhi, vol. 26, no. 5, pp. 266–269, 1997 (Chinese).
16. D. Mikulić, I. Ilić, M. Ćepulić, et al., “Tumor angiogenesis and outcome in osteosarcoma,” Pediatric Hematology and Oncology, vol. 21, no. 7, pp. 611–619, 2004. View at Publisher · View at Google Scholar
17. M. Kreuter, R. Bieker, S. S. Bielaek, et al., “Prognostic relevance of increased angiogenesis in osteosarcoma,” Clinical Cancer Research, vol. 10, no. 24, pp. 8531–8537, 2004. View at Publisher · View at Google Scholar · View at PubMed
18. E. T. Ek, J. Ojaimi, Y. Kitagawa, and P. F. Choong, “Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?,” Oncology Reports, vol. 16, no. 1, pp. 17–23, 2006.
19. J. H. Edmonson, H. J. Long, R. L. Richardson, E. T. Creagan, and S. J. Green, “Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas,” Cancer Chemotherapy and Pharmacology, vol. 15, no. 2, pp. 181–182, 1985. View at Publisher · View at Google Scholar
20. W. T. Beck, T. M. Grogan, C. L. Willman, et al., “Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations,” Cancer Research, vol. 56, no. 13, pp. 3010–3020, 1996.
21. H. J. G. Gundersen, “Notes on the estimation of the numerical density of arbitrary profiles: the edge effect,” Journal of Microscopy, vol. 111, pp. 219–233, 1977.
22. H. W. Chalkley, “Method for the quantitative morphologic analysis of tissues,” Journal of the National Cancer Institute, vol. 4, pp. 47–53, 1943.
23. P. B. Vermeulen, G. Gasparini, S. B. Fox, and C. Colpaert, “Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours,” European Journal of Cancer, vol. 38, no. 12, pp. 1564–1579, 2002. View at Publisher · View at Google Scholar
24. E. Vollmer, A. Roessner, J. Gerdes, et al., “Improved grading of bone tumors with the monoclonal antibody Ki-67,” Journal of Cancer Research and Clinical Oncology, vol. 112, no. 3, pp. 281–282, 1986. View at Publisher · View at Google Scholar
25. E. Vollmer, A. Roessner, P. Wuisman, A. Härle, and E. Grundmann, “The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67,” Current Topics in Pathology, vol. 80, pp. 91–114, 1989.
26. H.-R. Park and Y.-K. Park, “Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone,” Journal of Korean Medical Science, vol. 10, no. 5, pp. 360–367, 1995.
27. M. Pösl, M. Amling, M. Werner, et al., “Osteosarkom—apoptose und proliferation untersuchung zur bcl-2-expression,” Der Pathologe, vol. 15, no. 6, pp. 337–344, 1994. View at Publisher · View at Google Scholar
28. I. Stenzel, M. Pösl, H. Ritzel, M. Hentz, M. Werner, and G. Delling, “Zellproliferation bei knochentumoren immunhistologische untersuchung zur Ki-67-proteinexpression,” Der Pathologe, vol. 17, no. 1, pp. 56–62, 1996. View at Publisher · View at Google Scholar
29. M. G. C. T. van Oijen, R. H. Medema, P. J. Slootweg, and G. Rijksen, “Positivity of the proliferation marker Ki-67 in noncycling cells,” American Journal of Clinical Pathology, vol. 110, no. 1, pp. 24–31, 1998.
30. K. Okada, J. Nishida, T. Morita, H. Kakizaki, A. Ishikawa, and T. Hotta, “Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis,” Human Pathology, vol. 31, no. 6, pp. 633–639, 2000. View at Publisher · View at Google Scholar · View at PubMed
31. Y. Oda, T. Naka, M. Takeshita, Y. Iwamoto, and M. Tsuneyoshi, “Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study,” Human Pathology, vol. 31, no. 6, pp. 709–716, 2000. View at Publisher · View at Google Scholar · View at PubMed
32. K. Scotlandi, M. Serra, M. C. Manara, et al., “Clinical relevance of Ki-67 expression in bone tumors,” Cancer, vol. 75, no. 3, pp. 806–814, 1995. View at Publisher · View at Google Scholar
33. N.A. Hernández-Rodríguez, E. Correa, R. Sotelo, et al., “Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma,” Cancer Detection and Prevention, vol. 25, no. 2, pp. 210–215, 2001.
34. M. L. Jensen, B. Schumacher, O. M. Jensen, O. S. Nielsen, and J. Keller, “Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases,” American Journal of Surgical Pathology, vol. 22, no. 5, pp. 588–594, 1998. View at Publisher · View at Google Scholar
35. D. G. Stefanou, A. V. Nonni, N. J. Agnantis, S. E. Athanassiadou, E. Briassoulis, and N. Pavlidis, “p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study,” Anticancer Research, vol. 18, no. 6B, pp. 4673–4681, 1998.
36. B. Wadayama, J. Toguchida, T. Yamaguchi, M. S. Sasaki, Y. Kotoura, and T. Yamamuro, “p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas,” British Journal of Cancer, vol. 68, no. 6, pp. 1134–1139, 1993.
37. Y. Oda, B. Wehrmann, K. Radig, et al., “Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression,” General & Diagnostic Pathology, vol. 141, no. 2, pp. 97–103, 1995.
38. F. Lonardo, T. Ueda, A. G. Huvos, J. Healey, and M. Ladanyi, “p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate,” Cancer, vol. 79, no. 8, pp. 1541–1547, 1997. View at Publisher · View at Google Scholar
39. Y. Ueda, B. Dockhorn-Dwornizak, S. Blasius, et al., “Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone,” Journal of Cancer Research and Clinical Oncology, vol. 119, no. 3, pp. 172–178, 1993. View at Publisher · View at Google Scholar
40. R. Gorlick, A. G. Huvos, G. Heller, et al., “Expression of HER2/erbB-2 correlates with survival in osteosarcoma,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2781–2788, 1999.
41. T. Naka, T. Fukuda, N. Shinohara, Y. Iwamoto, Y. Sugioka, and M. Tsuneyoshi, “Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma,” Cancer, vol. 76, no. 6, pp. 972–984, 1995. View at Publisher · View at Google Scholar
42. P. A. Hall and D. P. Lane, “p53 In tumour pathology: can we trust immunohistochemistry? - revisited!,” The Journal of Pathology, vol. 172, no. 1, pp. 1–4, 1994. View at Publisher · View at Google Scholar · View at PubMed
43. A. Goto, H. Kanda, Y. Ishikawa, et al., “Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas,” Japanese Journal of Cancer Research, vol. 89, no. 5, pp. 539–547, 1998.
44. J. Toguchida, T. Yamaguchi, B. Ritchie, et al., “Mutation spectrum of the p53 gene in bone and soft tissue sarcomas,” Cancer Research, vol. 52, no. 22, pp. 6194–6199, 1992.
45. K. Radig, R. Schneider-Stock, C. Haeckel, W. Neumann, and A. Roessner, “p53 gene mutations in osteosarcomas of low-grade malignancy,” Human Pathology, vol. 29, no. 11, pp. 1310–1316, 1998. View at Publisher · View at Google Scholar
46. C. R. Walkley, R. Qudsi, V. G. Sankaran, et al., “Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease,” Genes & Development, vol. 22, no. 12, pp. 1662–1676, 2008. View at Publisher · View at Google Scholar · View at PubMed
47. C. W. Miller, A. Aslo, A. Won, M. Tan, B. Lampkin, and H. P. Koeffler, “Alterations of the p53, Rb and MDM2 genes in osteosarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 9, pp. 559–565, 1996. View at Publisher · View at Google Scholar
48. M.-K. A. Kaseta, L. Khaldi, I. P. Gomatos, et al., “Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma,” Journal of Surgical Oncology, vol. 97, no. 3, pp. 259–266, 2008. View at Publisher · View at Google Scholar · View at PubMed
49. Y. B. Park, H. S. Kim, J. H. Oh, and S. H. Lee, “The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma,” International Orthopaedics, vol. 24, no. 6, pp. 307–310, 2001. View at Publisher · View at Google Scholar
50. H. S. L. Chan, T. M. Grogan, G. Haddad, G. DeBoer, and V. Ling, “P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy,” Journal of the National Cancer Institute, vol. 89, no. 22, pp. 1706–1715, 1997. View at Publisher · View at Google Scholar
51. K. Radig, C. Hackel, J. Herting, et al., “Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype,” General & Diagnostic Pathology, vol. 142, no. 3-4, pp. 139–145, 1997.
52. M. Pösl, M. Amling, K. Grahl, et al., “P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An Immunohistochemical study,” General & Diagnostic Pathology, vol. 142, no. 5-6, pp. 317–325, 1997.
53. M. Serra, K. Scotlandi, M. C. Manara, et al., “Analysis of P-glycoprotein expression in osteosarcoma,” European Journal of Cancer, vol. 31, no. 12, pp. 1998–2002, 1995. View at Publisher · View at Google Scholar
54. S. Ferrari, F. Bertoni, L. Zanella, et al., “Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma,” Cancer, vol. 100, no. 9, pp. 1936–1942, 2004. View at Publisher · View at Google Scholar · View at PubMed
55. S. Kakar, M. Mihalov, N. A. Chachlani, L. Ghosh, and H. Johnstone, “Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma,” Journal of Surgical Oncology, vol. 73, no. 2, pp. 125–126, 2000. View at Publisher · View at Google Scholar
56. E. E. Pakos and J. P. A. Ioannidis, “The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis,” Cancer, vol. 98, no. 3, pp. 581–589, 2003. View at Publisher · View at Google Scholar · View at PubMed
57. K. Scotlandi, M. Serra, G. Nicoletti, et al., “Multidrug resistance and malignancy in human osteosarcoma,” Cancer Research, vol. 56, no. 10, pp. 2434–2439, 1996.
58. R. A. Trammell, C. B. Johnson, J. R. Barker, R. S. Bell, and D. G. Allan, “Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model,” Journal of Orthopaedic Research, vol. 18, no. 3, pp. 449–455, 2000. View at Publisher · View at Google Scholar · View at PubMed
59. F. J. Hornicek, M. C. Gebhardt, M. W. Wolfe, et al., “P-glycoprotein levels predict poor outcome in patients with osteosarcoma,” Clinical Orthopaedics & Related Research, no. 373, pp. 11–17, 2000. View at Publisher · View at Google Scholar
60. N. Baldini, K. Scotlandi, M. Serra, et al., “P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy,” Journal of Orthopaedic Research, vol. 17, no. 5, pp. 629–632, 1999. View at Publisher · View at Google Scholar · View at PubMed
61. S. D. Shnyder, A. J. Hayes, J. Pringle, and C. W. Archer, “P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma,” British Journal of Cancer, vol. 78, no. 6, pp. 757–759, 1998.
62. R. A. Kandel, S. Campbell, S. E. Noble-Topham, R. Bell, and I. L. Andrulis, “Correlation of P-glycoprotein detection by immunohistochemistry with mdr-l mRNA levels in osteosarcomas. Pilot study,” Diagnostic Molecular Pathology, vol. 4, no. 1, pp. 59–65, 1995. View at Publisher · View at Google Scholar
63. J. S. Wunder, S. B. Bull, V. Aneliunas, et al., “MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study,” Journal of Clinical Oncology, vol. 18, no. 14, pp. 2685–2694, 2000.
64. M. Kaya, T. Wada, T. Akatsuka, et al., “Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis,” Clinical Cancer Research, vol. 6, no. 2, pp. 572–577, 2000.
65. A. Handa, T. Tokunaga, T. Tsuchida, et al., “Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma,” International Journal of Oncology, vol. 17, no. 2, pp. 291–295, 2000.
66. B. L. Coomber, J. Denton, A. Sylvestre, and S. Kruth, “Blood vessel density in canine osteosarcoma,” Canadian Journal of Veterinary Research, vol. 62, no. 3, pp. 199–204, 1998.
67. S. Mori, T. Ueda, S. Kuratsu, N. Hosono, K. Izawa, and A. Uchida, “Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma,” International Journal of Cancer, vol. 61, no. 1, pp. 148–152, 1995. View at Publisher · View at Google Scholar
68. T. Morishita, Y. Mii, Y. Miyauchi, et al., “Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats,” Japanese Journal of Clinical Oncology, vol. 25, no. 2, pp. 25–31, 1995.
69. D. Harms, “New entities, concepts, and questions in childhood tumor pathology,” General & Diagnostic Pathology, vol. 141, no. 1, pp. 1–14, 1995.
70. M. O'Sullivan, V. Budhraja, Y. Sadovsky, and J. D. Pfeifer, “Tumor heterogeneity affects the precision of microarray analysis,” Diagnostic Molecular Pathology, vol. 14, no. 2, pp. 65–71, 2005. View at Publisher · View at Google Scholar
71. P. D. Lee, S. E. Noble-Topham, R. S. Bell, and I. L. Andrulis, “Quantitative analysis of multidrug resistance gene expression in human osteosarcomas,” British Journal of Cancer, vol. 74, no. 7, pp. 1046–1050, 1996.